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It is a fact that cigarette smoke (CS) has negative effects on patients with Crohn’s disease (CD), 
whereas CS seems to provide protection to patients with Ulcerative Colitis (UC). The mechanism 
of how CS ingredients or nicotine modulate inflammatory phenotypic response in IBD subsets 
remained unclear. Unlike UC, CD has been associated with genetic disposition, immuno-
dysregulation and infection by pathogens mainly Mycobacterium avium paratuberculosis (MAP). 
In this study, we investigated the cellular and molecular effects of pure nicotine and tobacco 
extracts from HLE-nicotine rich-plant and LAMD-nicotine less-plant in infected macrophages. 
Unlike LAMD extracts, Nicotine (4ug/mL) and HLE extracts (0.18%) significantly favored M2 
polarization and phenotypic response. While macrophages infected with MAP or treated with LPS 
promoted pro-inflammatory response, treatment of infected macrophages with nicotine/HLE 
extracts further elevated pro-inflammatory response, and enhanced MAP burden. Pre-conditioning 
macrophages with nicotine or blocking alpha-7nAChR with antagonist reversed the effect of 
nicotine in infected macrophages. We demonstrated that MAP infection in macrophages was 
mediated through TLR2/MyD88 signaling; blocking TLR2 and TLR4 with antagonists 
significantly reduced the inflammatory effect of MAP and LPS. Interestingly, nicotine in infected 
macrophages significantly downregulated TLR2/TLR4 expression, activated MyD88, and 
increased expression of pro-inflammatory cytokines. Surprisingly, dual treatment of MAP-
infected macrophages with MyD88 antagonist and nicotine absolutely impaired immune response 
during infection. The data shows a role for TLR2/MyD88 signaling in elevated inflammatory 
response during infection in CD smokers. Overall, we conclude that in absence of infection in UC, 
nicotine activates the cholinergic anti-inflammatory pathway through alpha-7nAChRs. However, 
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in CD smokers with MAP infection, nicotine action is mediated through TLR2/MyD88 signaling 
leading to significant inflammatory response. The study is the first to unmask the mechanism 
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CHAPTER ONE: BACKGROUND 
Note: This section has been published in part and the citation link is: AlQasrawi, D., Qasem, A., 
& Naser, S. A. (2020). Divergent Effect of Cigarette Smoke on Innate Immunity in Inflammatory 
Bowel Disease: A Nicotine-Infection Interaction. International Journal of Molecular 
Sciences, 21(16), 5801. 
Overview of Inflammatory Bowel Disease 
   Inflammatory bowel disease (IBD) is a chronic condition that involves severe inflammation in 
the lining of the digestive tract [1]. IBD which includes Crohn’s disease (CD) and Ulcerative colitis 
(UC) occurs more commonly in developed countries with an average incidence of 10 per 100,000 
persons [1]. IBD general symptoms include weight loss, bloody diarrhea, anemia, fever, rectal 
bleeding, severe ulceration and loss of appetite, which ultimately lead to poor quality of life [2,3]. 
The pathogenesis of IBD is still not fully understood. However, there are compelling evidence that 
support the association of IBD in genetically susceptible persons with environmental triggers 
including infection [4]. There are at least 200 genetic loci that have been identified as targets and 
may increase susceptibility to IBD [4]. For instance, variants of HLA haplotypes as HLA class II 
allele DRBI*0103 which have been strongly associated with UC, whereas Nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2) polymorphisms have been linked to CD [5]. 
NOD2 is the primary receptor responsible for intracellular bacterial recognition and clearance in 
tissue [5]. Other factors have been specifically associated with CD pathogenesis, and not UC, such 
as environmental triggers including diet, UV light exposure, vitamin D deficiency, infection, and 
tobacco smoking. Infection is well established as key complication in CD and not in UC 
pathogenesis [6]. Opportunistic enteric infections and zoonotic-linked pathogens have been 
reported exclusively in CD patients [4,7,8]. Among the most investigated pathogens in CD 
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etiology is Mycobacterium avium subspecies paratuberculosis (MAP) [7,8]. This fastidious acid-
fast bacillus is responsible for CD- like disease in ruminants with Johne’s disease [9]. On the other 
hand, tobacco smoking has been reported to have contradictory effects on IBD patients [10]. It 
alleviates the symptoms and provides protective effect in smokers with UC. The opposite is true 
in CD smokers; hence, it causes detrimental effect and exacerbates the symptoms [10,11]. Such 
contradictory effects among IBD patients was initially reported in a 1982 study by Harries et al., 
who observed a protective effects of tobacco smoking in UC patients and was harmful in patients 
with CD [10]. This observation has been confirmed and became well accepted by clinicians. The 
latter now recommend nicotine replacement therapy as a treatment option for some UC patients 
[10,11]. Smoking tobacco not just always exacerbates symptoms in CD patients, it also causes 
higher risk of relapse than non-smokers with CD [10,11]. 
   To understand this dogma in IBD subsets, our research team has been investigating the effects 
of cigarette smoke and nicotine on the cellular and molecular changes in CD- and UC-like 
macrophages. AlQasrawi et al., reported recently that they were able to mimic macrophages 
similar to those in CD and UC patients with history of prior or active cigarette smoking, and studied 
cellular response in presence and absence of active bacterial infection [12]. Among the findings, 
they elucidated how nicotine in UC active smokers activates the cholinergic anti-inflammatory 
pathway through α7-nicotinic acetylcholine receptor (α7nAChRs). This caused shift toward M2-
macrophage polarization, which resulted in upregulation of anti-inflammatory cytokines 
Interlukin-10 (IL-10), and downregulation of pro-inflammatory cytokines (IL-6 and tumor 
necrosis factor alpha (TNF-α)). They reported that decrease in caspase-3 activity was key factor 
in macrophage modulation toward anti-inflammatory phenotypic response [12]. On the other hand, 
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the effect of nicotine in macrophages infected with MAP, M. tuberculosis, or Klebsiella 
pneumoniae was contrary to that observed in UC-like macrophages [12]. These findings confirm 
the school of thought that bacterial infection plays a key role in CD pathogenesis. So, this study 
will focus more on interplay between infection and smoking and their effects on IBD patients. 
Cigarette Smoke is Detrimental in Crohn’s Disease 
   Many studies strongly support smoking as an independent risk factor of CD and even may affect 
the severity of the disease [Table 1]. CD patients who smoke or start smoking after diagnosis have 
higher numbers of relapses requiring greater immunosuppression that can lead to hospitalization, 
in comparison to patients who quit smoking or never smoked [11,13]. This was reported first in 
1984 by Holdstock et al. by analyzing 172 variables [14]. They reported that active CD smokers 
were more likely to be hospitalized due to a higher number of relapses and increased disease 
severity [14]. Another study reported the association of smoking with increased risk of relapsing 
in 152 CD patients (smokers vs. non-smokers) which suggested a twofold increased relapse rate 
among smokers as compared to non-smokers [15]. Other researchers investigated the effect of dose 
and duration of smoking in CD patients [16,17]. In a thirteen-years long study of almost 3000 CD 
patients, the harmful effect of smoking on CD patients was dose dependent causing heavy smokers 
to be at higher risk of needing immunosuppressants [16]. In this study, they divided CD patients 
into three groups: non-smokers, light smokers (1–10 cigarettes per day), and heavy smokers (> 10 
cigarettes per day), then they determined the annual disease activity and immunosuppressant 
requirement for each group [16]. Lindberg et al. investigated 231 CD patients and reported that 
heavy smokers (> 10 cigarettes per day) had an increased risk for surgery as well as higher risk of 
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further surgeries 10 years after diagnosis compared to non-smokers [17]. Limited studies reported 
contradictory observations where active CD smokers showed no negative effects as a result of CS 
[18]. 
   Genetics and/or ethnicity factors have been reported in the literature to influence the degree of 
how smoking impacts CD severity. Aldhous and Satsangi reported that there was no association 
between smoking and CD susceptibility among Jewish population [19]. Another study reported a 
higher percentage of smokers with CD in French Canadian populations compared to other 
Caucasian populations [19]. Most recently, researchers adapted different criteria for better CD 
stratification such as Vienna and Montreal classifications which depend on disease location and 
behavior [19]. Using these criteria, some suggested that smoking can progress CD stage toward 
fistulas or strictures formation while the location of the disease remains stable [20]. Another study 
reported that smoking has a strong association with the development of penetrating profile in non-
colonic CD [21]. On the other hand, several studies reported a lack of association between smoking 
and CD location and behavior [22]. Overall, all studies that found a direct link between smoking 
and CD concluded that smoking is more related to non-colonic and severe CD cases, whereas non-
smoking or light smoking may be associated with colonic and benign CD. 
Cigarette Smoke is a Protective Factor in Ulcerative Colitis 
   Paradoxically, smoking has been a favorable and protective environmental association in patients 
with UC [10]. This protective association between smoking and UC was first noted in 1976 by 
Samuelsson et al. who attributed this observation to interactions with medication [23]. Five years 
later, Harries et al. confirmed the protective effect of smoking in UC patients by analyzing data 
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from 230 UC patients and 192 CD patients. They concluded that only 8% of UC patients were 
current smokers compared to 42% of CD patients [24]. They reported that 44% of UC patients and 
27% of CD patients were ex-smokers [24]. A British study in 1998 involving 51 UC patients 
established that smoking has a positive effect on UC [25]. Further supporting evidence of the 
beneficial effects of smoking on UC were revealed by a subsequent study which concluded that 
resuming smoking in low doses can be used as a medication instead of steroids in ex-smokers with 
refractory UC [26]. A recent Hungarian study of 1420 IBD patients, including 914 UC patients 
and 506 CD patients, found that the effect of smoking on IBD is linked to gender and age, and it 
is most prominent in young adults [27]. They also showed that the prevalence of smoking is 14.9% 
in UC patients and 47% in CD patients [27]. This study was in line with a meta-analysis by Mahid 
et al. who confirmed the protective role of smoking on UC, with a 0.85 odd ratio (OR) of current 
smokers, as compared to lifetime non-smokers [28]. Further studies investigating the relationship 
between smoking and UC observed that smoking tends to be dose-dependent in UC patients 
[29,30]. A study examining 499 UC patients found that relatively heavy smokers with UC have 
healthier colons and less histological evidence of inflammation in colonoscopy examinations than 
light smokers [29]. Prior to that, a Japanese study also revealed a significant dose-response relation 
between smoking and UC among Japanese people [30]. Subsequent studies have confirmed the 
observation that current smokers with UC have less relapses, reduced need for immunosuppressant 





   Interestingly, different nicotine replacement forms have been recently recommended by 
clinicians to help UC patients. This includes transdermal patches, chewing gum, and nicotine-
based enemas [31]. In a study where 72 active UC patients were treated with either transdermal 
nicotine patches or placebo patches for six weeks, they found that transdermal nicotine 
replacement was significantly more effective than the placebo at reducing the severity of UC. They 
also reported serious side effects such as headache, nausea, sleep disturbance, and acute 
pancreatitis [32]. However, using nicotine enema or oral capsule formulations significantly 
decreased these side effects [33]. Another study claimed that chewing nicotine gum exerted the 
same positive influence on UC severity as observed in current smokers [34]. 
The Contradictory Effect of CS on IBD subsets is due to Nicotine-multifactorial interaction 
Nicotine and the other factors 
   Tobacco leave extracts contain roughly 4500 components, and around 150 of those have been 
labeled as harmful to human health such as dioxins which is known to be both carcinogenic and 
an immunomodulator [10]. Heavy metals such as cadmium and arsenic are also considered to be 
carcinogenic in addition to their role in the development of gastric ulcers [35]. Despite all the 
carcinogenic or toxic effects of these components in human health, nicotine remains the most 
active agent in tobacco which is thought to have the greatest effect. Nicotine is an alkaloid found 
naturally in the roots and leaves of the nightshade family of plants, such as Nicotiana tabacum. 
Although nicotine itself is not toxic, it is considered highly addictive component of tobacco [12]. 
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This may explain why most recent studies are mainly focused on establishing the role of nicotine 
in IBD pathogenesis. 
   Despite the extensive studies about the involvement of nicotine in IBD pathogenesis, the 
mechanisms by which nicotine modulates immune response in CD and UC require more 
elucidation. We propose that these mechanisms require a multi-factorial interaction between 
nicotine and the immune system, dysbiosis leading to infection, or epigenetic as illustrated in 
Figure 1. 
Nicotine and Immune Response: 
Cytokines 
   Nicotine is known to have a suppressive effect on both innate and humoral immune systems [12]. 
Many studies showed that nicotine inhibits TNF-α release from mononuclear cells isolated from 
healthy volunteers, while it stimulates the secretion of IL-10, which is known as an anti-
inflammatory cytokine [12]. The inflammatory process in CD has been looked at predominantly 
as a humoral response by activation of Th1/Th17 cells, which in turn converts the inflammatory 
response to be more harmful [3]. Moreover, smoking leads to an elevation of pro-inflammatory 
cytokines including TNF-α, interferon gamma (IFN-γ), IL-23, IL-6 and IL-1β, both in the gut and 
peripheral blood of CD patients [3]. Consequently, this exacerbates inflammation and triggers CD 
symptoms [3]. Meanwhile, the effect of nicotine on innate immunity (monocyte/macrophage) in 
CD remains to be elucidated. 
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α7nAChR in Immune Cells 
   It is well-known that nicotine activates cells through α7nAChR, which is responsible for the 
activation of cholinergic anti-inflammatory pathway [12]. The presence of α7nAChR on the cell 
surface of monocytes and macrophages adds to the role of nicotine in innate immune response 
[12,36]. Infection triggers acetylcholine (Ach) release by the vagal nerve, which binds with α7-
nAChR on the surface of macrophages and subsequently interferes with the production of pro-
inflammatory cytokines [37]. Surprisingly, nicotine has the same effect as that of vagal nerve 
stimulation leading to anti-inflammatory response by shifting the macrophage polarization toward 
M2, weakening the production of pro-inflammatory cytokines and increasing the secretion of anti-
inflammatory cytokines as well [12,37]. Moreover, activation of α7nAChR in CD4+ CD25+ 
regulatory T-cells is responsible for an immunosuppressive effect by producing IL-2 and 
downregulating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ҝB) [37]. To 
confirm this, other studies claimed that the presence of α7nAChR in endothelial cells may help in 
reduction of chemokines and adhesion molecules during inflammation [38]. These findings may 
explain again the cholinergic anti-inflammatory protective effects of nicotine among UC patients. 
However, limited studies have looked at how the innate immune response interacts with the overall 
inflammatory process in IBD, and the role of nicotine in macrophage recruitment, proliferation, 
and differentiation in CD vs. UC. 
Microbial Dysbiosis: 
   The gut microbial diversity and load have been studied in IBD. Dysbiosis occurs in IBD as 
defined by decrease in gut microbial diversity with shifting the balance between beneficial and 
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pathogenic bacteria, which may lead to aberrant immune response in genetically susceptible 
individuals [39]. In CD patients, enteric dysbiosis is common, which is represented by significant 
reduction in commensal phyla such as Firmicutes and Actinobacteria, with a higher presence of 
proteobacteria phyla [40]. Many studies have looked to the role of microbial dysbiosis in initiation 
of pathogenic infection such as Clostridium difficile in CD [41]. However, Further investigation 
is needed to elucidate the effect of disturbance of intestinal microbial equilibrium in inducing MAP 
infection in CD. Among UC patients, gut dysbiosis has been also reported, but the bacterial 
diversity was not disrupted as much as in CD [40]. Many recent studies have demonstrated the 
role of the gut microbiome as a link between smoking and CD [10,42,43]. Significant increases in 
Bacteroides-Prevotella abundance in smoker CD patients, compared to non-smokers have been 
detected through fluorescent in situ hybridization using 16S rRNA sequencing [42]. On the other 
hand, smoking cessation resulted in a high abundance of Firmicutes (Clostridium coccoidos, 
Eubacterium rectale, and Clostridium leptum), Actinobacteria (high guanine and cytosine content 
bacteria (Propionibacteriaceae & Bifidobacteria)), and a decrease in Bacteroidates (Prevotella 
spp. and Bacteriods spp.) [43]. This observation may prove that nicotine withdrawal plays a major 
role in the shifting of microbial composition towards the composition of healthy individuals. 
Epigenetic Susceptibility: 
   The term “epigenetic” refers to heritable changes of gene expression events, which is caused 
independently of genetic information from the primary DNA sequence [44]. The main epigenetic 
mechanisms include DNA methylation, histone modification, as well as microRNA (miRNA) [44]. 
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Recently, many studies proposed that epigenetic mechanisms could improve our understanding of 
IBD, which may lead to new insights of treatment options [44]. 
   Noncoding MicroRNAs (miRNAs) pathways such as miRNA-18b (miR-18b), miRNA-140 
(miR-140), and miRNA-124 (miR124) explains one of the epigenetic mechanisms by which 
nicotine regulates gene expression of pro-inflammatory cytokines [45]. miR-124 was claimed to 
be a critical mediator of inflammation which negatively controls its progression [45]. In many 
cases, it has been shown that nicotine can specifically upregulate miR-124 levels via α7nAChR in 
macrophages during sepsis [45]. Subsequent studies demonstrated that nicotine could exert an anti-
inflammatory response in DSS colitis (resembling UC) by elevating miR-124 levels [46]. 
However, elevation of mir-124 in TNBS-induced experimental colitis (resembling CD) was found 
to worsen the inflammation while blocking miR-124 could alleviate the symptoms [47]. 
   Nicotine has been shown to be responsible for miR-124 elevation in samples in both UC and 
CD, while the latest has contradictory effect in the two diseases [48]. Recently, a study by Qin et 
al., has also demonstrated that miR-124 might mediate the bivalent effect of nicotine on IBD by 
shifting the Th1/Th2 balance toward Th1 [48]. Consequently, miR-124 could be a suitable target 
for the contrasting treatment of IBD; up-regulation in UC and down-regulation in CD. Overall, a 
broad knowledge about the role of nicotine in epigenetic modifications in IBD patients is still 
lacking. However, this could offer novel treatment options for IBD patients, considering miRNAs 
as potential therapeutic targets. 
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Differences in Immunological Response Profile between Crohn’s Disease and Ulcerative 
Colitis 
   One of the most debated explanation for the contradictory effect of nicotine is the association of 
CD with microbial infection, which lacks in UC. Among the most discussed pathogens associated 
with CD is MAP [7,8,49–58]. 
   MAP is an intracellular pathogen capably of modulating the innate immune response in CD 
leading to significant production of pro-inflammatory cytokines [7]. It was reported that 
monocytes and macrophages in CD patients express Toll-Like Receptor (TLR) at higher levels 
compared with UC patients [59]. TLRs are pattern recognizing receptors in innate immune cells 
where the cytoplasmic domain is linked to Myeloid differentiation primary response-88 (MYD-
88). The latter activates transcription factors such as NF- ҝB to produce pro-inflammatory 
cytokines. Although there are at least 10 types of TLR, TLR2 binds to MAP through the cell wall 
lipoarabinomannan (LAM) which initiate the activation of the NF- ҝB pathway and production of 
pro-inflammatory cytokines [60]. Different types of receptors are responsible for MAP uptake 
such as scavenger, mannose receptors as well as complement receptors, which are mainly 
responsible for internalizing opsonized MAP. TLRs are considered as the sole receptors for 
immune response and activation of the pro-inflammatory pathway by recognition of 
lipoarabinomannan in the surface of macrophages mimicking CD macrophages. Figure 2 shows 
illustration of how MAP and its cell wall components interact with TLR during phagocytosis and 
inflammatory response. 
   The effect of nicotine on IBD patients is clearly demonstrated through changes to gastrointestinal 
tissue. However, the effect of nicotine and smoking on respiratory tract is well established. The 
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similarity between intestinal inflammatory response in CD smokers and others with pulmonary 
inflammation is well studied and reported in the literature. Specifically, the effect of smoking on 
tuberculosis and exacerbating of infection has been well elucidated [40,12]. For example, TB 
smokers are known to have higher levels of alveolar macrophages compared to non-smoker and 
former TB smokers [61,62]. Bai et al. demonstrated that nicotine impairs anti-MTB defense 
leading to increase survival and burden of the bacterium in macrophages through α7nAchR by 
decreasing apoptosis and activation of the NF-ҝB family [63]. We reported similar finding when 
we studied the effect of nicotine on macrophages infected with related microorganisms such as 
MAP [12]. We validated our findings in CD- and UC-like macrophages and our conclusion should 
help explain the contradictory effect of smoking on IBD subsets. 
   Several mechanisms may explain the protective effect of nicotine on innate immunity in UC. 
First, nicotine’s effect is mediated by activation of the cholinergic anti-inflammatory pathway via 
α7nAChR, on macrophages, monocytes and dendritic cells [40]. This causes a shift in macrophage 
polarization towards M2 and elevation of IL-10 and decrease pro-inflammatory cytokines levels 
such as IL-6, IL-12 and TNF-α [38]. Other studies reported that T cells possess α7nAChR, which 
can be activated by nicotine in Th2 cells and Treg cells, therefore inducing them to produce IL-10 
and TGF-β [40]. Second, nicotine was also found to induce production of miR-124, which has an 
inhibitory effect on pro-inflammatory cytokine production in LPS-induced macrophages [45]. 
MiR-124 inhibits the translation of TNF-α converting enzyme, therefore preventing the conversion 
of pro-TNF-α to TNF-α [45] [Figure 3]. 
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Summary and Outlook 
   Activation of α7nAChRs downregulates the production of pro-inflammatory cytokines, 
including TNFα, IL-6 and IL-1β [64]. The downstream signaling to these receptors in macrophages 
involves NF-kB pathway, whereas in T cells anti-inflammatory effect requires further 
investigation, although stimulation of α7nAChRs in T cells showed anti-inflammatory effects 
[38,65]. Several epidemiological studies showed a clear lower correlation between smokers and 
the incidence of UC in particular [66]. Nicotine was found as the active ingredient in CS, which is 
responsible for this immunosuppressive mechanism [67]. On the other hand, CS was associated 
with higher incidence of numerous inflammatory disorders including Rheumatoid Arthritis (RA), 
atherosclerosis, peptic ulcer disease and CD [66]. This complex effect of nicotine in inflammation 
is not well understood, but we speculate that the presence of certain pathogens will shift the anti-
inflammatory role of nicotine to pro-inflammatory factor. 
   In conclusion, CS plays a contradictory role in IBD subsets; it is a risk factor in CD development 
and provides protection in UC. Our most recent in vitro study was the first to provide significant 
insights toward understanding the cellular events involved in the mysterious divergent effects of 
CS ingredients on IBD patients [12]. Nicotine exacerbates MAP infection in macrophages in CD 
patients causing shift toward M1 polarization and excessive production of pro-inflammatory 
cytokines. The opposite is true in UC; nicotine activates the cholinergic pathway providing anti-
inflammatory effect which provides a treatment option for many of UC patients. Figure 4 illustrates 
the effect of nicotine on macrophage modulations in IBD smokers. Studying the molecular process 
and the crosstalk between TLR signaling and miR-124 will further help in understanding why CS 





Figure 1:Effect of multi-factorial interaction and nicotine on IBD pathogenesis. 
 
 












Figure 4:Schematic Illustration of the Effect of Cigarette Smoke and Nicotine on 







Table 1:  List of Clinical Studies investigating the Effect of Tobacco Smoking on CD patients. 









Holdstock et al (1984) [14] 
Somerville et al (1984)  [13] 
Timmer et al (1998) [15] 
Lindberg et al (1992) [17] 
Seksik et al (1995-2008) [16] 




















172 IBD patients 
82 variables 
152 CD patients 
231 CD patients 
3000 CD patients 
820 CD patients 
Smoking leads to CD rather than UC 
CD patients are more likely to smoke 
Increased rate of relapses in CD smoker patients 
CD heavy smokers have an increased risk of surgery 
Smoking has a dose-dependent effect on CD patients 
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230 UC patients 
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499 IBD patients 
 
15 UC patients 
 
1420 IBD patients 
Low rate of smokers among UC patients 
Low rate of smokers among UC patients 
The relationship between smoking and UC is dose-
dependent 
UC is a non-smoker disease 
UC heavy smokers have healthier colons than UC 
light smokers 
Low doses of smoking can be used as a medication 
in ex-smoker refractory UC patients 
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CHAPTER TWO: MYSTERY SOLVED: WHY SMOKE EXTRACT WORENS DISEASE 
IN SMOKERS WITH CROHN’S DISEASE AND NOT ULCERATIVE COLITIS? GUT 
MAP! 
Note: This section has been published in part and the citation link is: AlQasrawi, D., Abdelli, L. 
S., & Naser, S. A. (2020). Mystery Solved: Why Smoke Extract Worsens Disease in Smokers 
with Crohn’s Disease and Not Ulcerative Colitis? Gut MAP!. Microorganisms, 8(5), 666. 
Introduction 
   Cigarette smoke (CS) is considered an independent risk factor in the development of Crohn’s 
disease (CD) [1–3]. It is associated with exacerbated inflammatory relapses, postoperative 
recurrence, and poorer response to medical therapy [1–3]. A standard clinical practice for newly 
diagnosed CD patients is to quit CS to avoid the aforementioned debilitating consequences [4,5]. 
Generally, CS causes CD smokers to suffer from exacerbated inflammatory symptoms, severe 
phenotypical presentation of the disease, and in many cases leads to the patient’s hospitalization 
and poor long-term prognosis [6–9]. On the contrary, CS seems to be surprisingly protective in 
patients with ulcerative colitis (UC), which is largely known as the disease of the non-smokers 
[3,5]. Inflammatory symptoms in UC are significantly decreased when tobacco is consumed, while 
smoking cessation results in abrupt flares of inflammation and more frequent relapsing episodes 
in these patients [10]. UC patients with history of smoking usually acquire their disease few years 
after they stop smoking, suggesting that smoking protected them from acquiring the disease earlier 
[11]. Unlike UC, the etiology of CD has been vigorously researched and debated and now it is 
generally accepted that CD is associated with microbial infection, immune-dysregulation, and 
mucosal dysfunction. Among the most debated pathogens that have been studied for possible roles 
in CD pathogenesis are Mycobacterium avium subsp. paratuberculosis (MAP), adherent-invasive 
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Escherichia coli (AIEC), and Klebsiella pneumoniae [12–14]. The mechanism of how CS 
ingredients induce pro-inflammatory or anti-inflammatory phenotypes in IBD remained unclear. 
This study is not about what causes CD; it is about understanding the mechanism involved in how 
CS affects macrophages infected with microorganisms associated with CD pathogenesis. The 
monocytic response against intracellular bacterial infection such as MAP is usually mediated by 
TLR2 receptor through the recruitment of cytoplasmic adaptor protein and activation of 
intracellular signaling molecules, which lead to phagosome maturation and synthesis of pro-
inflammatory cytokines like TNF-α, IL-6, IL-8, IL-12, and IL-23 [15,16]. 
   Nicotine, an addictive immunosuppressant ingredient in CS, is known to decrease the level of 
pro-inflammatory cytokines, inhibit dendritic cells, and prevent cell apoptosis [17,18]. Nicotine 
also decreases the production of cathelicidin, anti-microbial peptide, and inhibits formation of 
granuloma [19,20]. The concentration of nicotine in active cigarette smokers ranges between 4 and 
72 ng/mL [21]. Although smokeless tobacco products, including e-cigarettes and smoking 
cessation nicotine-replacement products, are labeled as somewhat safe, the level of nicotine in the 
user’s blood can exceed the level achieved by cigarette smoking [22]. Tobacco-use is the leading 
cause of preventable disease and death in the United States [23]. Nearly half a million Americans 
die prematurely due to smoking or secondhand smoking exposure [23]. Another 16 million 
Americans live with serious illnesses caused by cigarette smoking [5]. Nicotine as a potent alkaloid 
is considered to be the most addictive and pharmacologically active substance among the many 
compounds present in tobacco products. 
   Limited studies have investigated how the innate immune response interplays in the overall 
inflammatory process involved in IBD and what effects nicotine has on macrophage recruitment, 
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proliferation, and phenotypic response in CD and UC subsets. One clear link between innate 
immune cells and CS is the presence of a nicotinic acetylcholine receptor α7 (α7-aAChR) on 
monocytes and macrophages cell surface [24]. Experimental studies have demonstrated that 
nicotine inhibits pro-inflammatory cytokine release from in vitro monocytes-based cell culture 
[24]. However, this does not explain the conflicting effects of CS on UC and CD symptoms. 
Generally, monocytes respond to direct stimuli by differentiating into classical pro-inflammatory 
M1 cells or alternative anti-inflammatory M2 macrophages [25]. M1 releases IL-1b, MCP-1, 
iNOS, IL-6, IL-8, IL-12, IL-23, and TNF-α, while M2 macrophages release IL-10, IL-1Ra, and 
higher levels of arginase-1. The latter inhibits nitric oxide production and reduces inflammation 
[25]. This study is designed to study the mechanism of how CS or its most abundant and active 
ingredient, nicotine, modulates α7aAChR on macrophages infected with intracellular pathogens 
and elicit inflammatory response. Specifically, the study focused on investigating the effect of CS 
and nicotine on the cellular processes in THP-1 infected with MAP, or LPS derived from AIEC, 




Materials and Methods 
Culture Conditions of THP-1 Macrophages 
   THP-1 monocytes (ATCC TIB-202) were cultured as described earlier [26]. Briefly, cells were 
maintained in a RPMI-1640 growth medium (Invitrogen, Carlsbad, CA, USA) containing 10% 
fetal bovine serum (FBS) (Invitrogen) and 0.09% β-mercaptoethanol and maintained in a 
humidified 5% CO2 incubator at 37 °C until they reached 80% confluency. Then, cells were 
activated by adding 50 ng/mL of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. 
Louis, MO, USA) for 48 h. All experiments were performed in quadruplicates and done within 12 
passages.  
Infection and Treatment of THP-1 Macrophages 
   Infection: activated THP-1 cells (M0 macrophages) were plated at a density of 3 × 105 cells in 
12 well plates. Cells were infected for 24 h at 37 °C in 5% CO2 with 1 × 10
7 CFU/mL of MAP 
strain UCF4 (a clinical strain isolated from CD patient), Mycobacterium tuberculosis ATCC 
HR237, or Klebsiella pneumoniae ATCC13883. Bacterial Lipopolysaccharide (LPS) from 
Escherichia coli strain O111.B4 (Sigma Aldrich, 1 µg/mL) and uninfected cells were used as a 
control.  
   Treatment with CS extracts and nicotine: activated THP-1 macrophages were treated with 
nicotine (0 to 4 µg/mL, Sigma-Aldrich), 0.18% CS extracts from HLE-Petit Havana (tobacco 
leaves rich with nicotine), or 0.18% germplasm line of Maryland tobacco (LAMD, tobacco leaves 
with nicotine-less) for 24 h at 37 °C in 5% CO2. HLE and LAMD tobacco leaves were generously 
provided by Professor Henry Daniel (University of Pennsylvania). 
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   Nicotine Receptor Inhibitor: To determine the role of α7nAchR in the cellular uptake of CS and 
nicotine, macrophages were treated with mecamylamine (MEC), an α7nAChR antagonist (Fisher 
Scientific). Macrophages were pretreated with 0, 25, 50 and 75 µM of MEC at room temperature 
for 30 min prior to nicotine or CS treatments. All experiments were performed in quadruplicates. 
Measurement of Relative Gene Expression Using RT-PCR 
   RNA Isolation: cell pellets were collected in 2 mL-microcentrifuge and suspended in 500 µL of 
TRIzol ® reagent (Invitrogen). A total of 125 µL of chloroform was added to each tube, mixed, 
and incubated at room temperature for 5 min. Following centrifugation at 10,000 rpm for 5 min, 
the aqueous phase was transferred to a new tube and mixed with 275 µL isopropanol. Following 
centrifugation at 14,000 rpm and 4 °C for 15 min, RNA pellets were isolated, washed in 500 µL 
of 75% ethanol, air-dried, and then dissolved in 15 µL of Tris-EDTA (TE) buffer. RNA 
concentration and purity were analyzed using Nonodrop OneC (ThermoFisher) and stored at –80 
°C until further use. 
   cDNA Synthesis: Reverse transcription reaction was carried out by adding 800 ng of RNA in 
0.25-mL microtubes containing 20 µL of PCR reaction, 4 µL iScript™ Reverse transcription (Bio-
Rad®, Hercules, CA, USA) and up to 0.2 mL RNAse-free water. The reaction was performed 
using MyGene Series Peltier Thermal Cycler under the following conditions: 5 min at 25 °C, 
20 min at 46 °C, and 1 minute at 95 °C.  
   RT-PCR: Gene expression analysis was performed as described earlier [27]. Briefly, a total 
volume of 20 µL reaction mixture containing 1 µL of cDNA (30 ng/µL), 10 µL of Fast SYBR 
Green Mastermix (Thermo Fisher Scientific, Waltham, MA, USA), 1 µL of either iNOS, CD206, 
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IL-6, TNF-α, or IL-10, PrimePCR SYBER Green Assay mixes (Bio-Rad®, California, USA), and 
8 µL of RNAse-free water were prepared in a 96-well Microamp RT-PCR reaction plate and 
analyzed using 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, United 
States). Housekeeping GAPDH primer (Bio-Rad®, California, USA) was used to obtain baseline 
CT readings. Relative mRNA expression was calculated by using the equation 2(−∆CT), where ∆CT 
= [(Sample RT-PCR CT value) − (GAPDH CT baseline value)] × 1000.  
Measurement of Cytokines and Cell Surface Markers 
   For cell surface markers, cell pellets were incubated with ice RIPA buffer (Thermo-Fisher, Cat# 
89901, Massachusetts, USA) for 15 min, then centrifuged at 14,000 rpm for 20 min. Supernatant 
containing cell lysates were analyzed using ELISA kits: iNOS (LS-Bio; Washington, USA, Cat# 
LS-F39142), CD206 (Sigma-Aldrich; Cat# RAB1178, Missouri, USA) following manufacturer’s 
instructions. Cell culture supernatants were used to measure cytokine levels: IL-6 (LS-Bio; Cat# 
LS-F9754, Washington, USA), TNF-α (LS-Bio; Cat# EH3TNFA, Washington, USA), and IL-10 
(Sigma-Aldrich; Cat# KHC0101, Missouri, USA). All ELISA experiments were done in 
triplicates.  
Bacterial Viability Assay  
   Following the infection, macrophages were washed twice with PBS to remove extracellular 
bacteria, then lysed using cold RIPA buffer (Thermo-Fisher, Cat# 89901, Massachusetts, USA) 
for 15 min. Cell lysates were centrifuged at 14,000 rpm for 20 min and the supernatant was 
collected to perform bacterial viability using the Live/Dead Baclight Bacterial Viability Kit 
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(Molecular Probes, Inc., Eugene, OR, USA), as described earlier [26]. All viability experiments 
were performed in triplicates. 
Measurement of Macrophage Apoptosis 
   In order to examine the apoptotic pathway induced by nicotine, caspase-3 colorimetric assay 
(Abcam, Cambridge, UK) was used as described earlier [26]. Briefly, following infection and 
treatment, THP-1 cells were washed twice with PBS, collected and lysed using chilled Cell Lysis 
Buffer. Total protein levels were analyzed using DEVD-pNA as a caspase-3-specific substrate. 
After incubation at 37 °C for 1–2 h, absorbance was measured at 400–405 nm in a SpectraMax i3x 
plate reader. All apoptosis experiments were done in duplicate (n = 2) with each sample loaded in 
triplicate and the average was calculated. 
Statistical Analysis 
   All data collected in this study were pre-tested for normal distribution using the Kolmogorov–
Smirnov normality test followed by Unpaired Two-tailed t test. p < 0.05 and a 95% confidence 
interval (CI) were used for the assessment of differences in all experiments. Data were presented 




Determination of Ingredient(s) in CS Extracts Active in Modulating Macrophages Response 
   In order to determine the active ingredient(s) in tobacco leaves that modulate inflammatory 
response in macrophages, we measured M1 (iNOS) and M2 (CD206) markers, IL-6, TNF-α, and 
IL-10 expression in PMA-activated THP-1, and macrophages infected with MAP following a 
treatment with CS extracts from HLE-Petit Havana (nicotine-rich) and LAMD (nicotine-less). We 
estimated that 0.18% of HLE-Petit Havana contains 4 µg/mL nicotine [28]. Accordingly, we used 
0.18% HLE-Petit Havana extracts in parallel to pure nicotine (4 µg/mL) and 0.18% of LAMD 
tobacco. Experiments were also performed with LPS-derived from AIEC. MTB was included as 
control. 
Uninfected Cells 
   Although the effect of CS extracts from both HLE and LAMD on iNOS, CD206, IL-6, and TNF-
α was mostly similar (Figure 5A–D), expression of IL-10 was significantly low in LAMD-treated 
cells (0.22 ± 0.021; p < 0.05) compared to HLE-treated cells (0.40 ± 0.033; p < 0.05; Figure 5E). 
Likewise, the effect of nicotine on iNOS, IL-6, and TNF-α was not significant, but it increased the 
expression of CD206 (3.84 ± 0.06 vs untreated cells 2.46 ± 0.08; p < 0.05; Figure 5D) and IL-10 




In Absence of CS Extracts and Nicotine 
   Infection of macrophages with MAP increased iNOS expression (13.09 ± 0.94 vs 5.11 ± 0.8 in 
uninflected cells), IL-6 (38.43 ± 1.2 vs 18.5 ± 1.8 in uninfected cells), and TNF-α (0.54 ± 0.075 vs 
0.27 ± 0.08 in uninflected cells).  
In Presence of CS Extracts and Nicotine 
   We also evaluated the effect of CS extracts from both HLE and LAMD, as well as nicotine on 
macrophages infected with MAP, and the outcome was surprisingly unexpected (Figure 5). CS 
extracts from HLE and nicotine both further increased iNOS expression in MAP-infected 
macrophages compared to CS extracts from LAMD and uninfected cells (HLE: 20.49 ± 0.4; 
nicotine: 15.64 ± 1.05; LAMD: 11.76 ± 1; and uninfected: 13.09 ± 0.94; p < 0.05; Figure 5A). The 
outcome was validated by a measurement of corresponding cytokines. Expression of IL-6 and 
TNF-α increased in MAP-infected macrophages and subsequently treated with CS extracts of HLE 
or nicotine compared to CS extracts of LAMD and untreated cells (HLE: 59.8 ± 1.4; nicotine: 44.5 
± 1.5; LAMD: 28.5 ± 2; and uninfected: 18.5 ± 1.8; p < 0.05 for IL-6) and (HLE: 2.7 ± 0.04; 
nicotine: 2.4 ± 0.05; LAMD: 1.7 ± 0.07; and uninfected: 0.27 ± 0.0.08; p < 0.05 for TNF-α; Figure 
1B–C). The effect on CD206 and IL-10 expression was not significant (Figure 5D,E). 
Effect of Nicotine on Macrophages Response is Dose-Dependent  
   The effect of nicotine dosage on macrophage polarization and response was investigated. 
Activated THP-1 cells were treated with ascending concentrations of nicotine (0, 2, and 4 µg/mL) 
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for 24 h followed by RT-PCR and ELISA evaluation of the expression and production of iNOS 
and CD206 markers. As shown in Figure 6 (A: gene expression, and B: protein levels), iNOS (M1) 
gradually decreased and CD206 (M2) increased in the dose-dependency of nicotine (p < 0.05). 
Based on these two markers’ gene expression, the percentage of M1, M2, and undifferentiated M0 
macrophages were calculated in presence and absence of nicotine. Untreated cells were 
differentiated into M1:M2 macrophages with a ratio of 9:1 of M1:M2 (calculated from black bars 
in Figure 2A). Figure 6C depicts how nicotine treatment shifts this ratio. In fact, nicotine treatment 
at 2 µg/mL starts to shift polarization with a ratio of 42% M1 vs 34.5% M2 and 23.5% M0 cells 
while 4 µg/mL nicotine further increased M2 macrophages to 50.09% against 32.34% M1 and 
around 17.57% undetermined M0 cells. Gene expression and protein levels of IL-6, TNF-α, and 
IL-10 were also illustrated in Figure 6D, E, respectively. Data indicate that an ascending 
concentration of nicotine correlates with decreased IL-6 and TNF-α gene and protein expression, 
which is reflective of the decreased M1 polarization marker iNOS. Accordingly, anti-inflammatory 
IL-10 gene expression and not protein significantly increased with 2 and 4 µg/mL nicotine 
treatment.  
Effect of Nicotine on Macrophages is Mediated through α7nAChRs 
In Absence of Infection 
   To determine if nicotine modulates macrophages and shifts polarization to anti-inflammatory 
response is mediated through α7nAChRs, we blocked nAchR with mecamylamine (MEC), an 
nAchR antagonist. Specifically, activated THP-1 macrophages were pretreated with 0, 25, 50 and 
75 µM MEC, followed by 4 µg/mL of nicotine. As shown in Figure 7A, in absence of MEC, 
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nicotine significantly decreased the iNOS level (6.25 ± 0.32 compared to 9.5 ± 0.25 in 
macrophages not treated with nicotine; p < 0.05). Preconditioning cells with MEC (25 to 75 µM) 
gradually neutralized the effect of nicotine on iNOS and reached its optimum effect at 50 µM 
(Figure 7A). A similar effect was also observed on TNF-α expression (Figure 7B). Likewise, 
pretreatment of macrophages with MEC has altered the effect of nicotine on CD206 (MEC 50 µM 
+ nicotine 4 µg/mL: 29.97 ± 2.45 vs MEC 50 µM: 25 ± 1.81 vs MEC 0 µM control: 30.5 ± 2.82; 
p < 0.05), Figure 7C, and IL-10 (MEC 50 µM + nicotine: 6.47 ± 0.56 vs MEC 50 µM: 6.5 ± 0.56 
vs MEC 0 µM control: 7.8 ± 0.84; p < 0.05), Figure 7D. 
During Infection 
   To explain why smokers with CD experience heightened inflammatory episodes compared to 
non-smoking CD patients or UC patients, we infected activated THP-1 with MAP for 24 h 
followed by treatment with 4 µg/mL nicotine. MTB and LPS were also used as controls. As 
expected, all infections resulted in a significant increase in pro-inflammatory status as evidenced 
by increased expression of iNOS, IL-6, and TNF-α (Figure 8A–C). Interestingly, adding nicotine 
treatment to infected macrophages almost doubled iNOS readings across all infections (MAP + 
nicotine: 55.7 ± 2.02 vs MAP alone: 22.94 ± 2.87), (MTB + nicotine: 77.15 ± 1.6 vs MTB alone: 
29.81 ± 0.81. p < 0.05), or (LPS + nicotine: 80.39 ± 1.83 vs LPS alone: 35.16 ± 2.04; p < 0.05). 
The significance effect was also observed when compared with untreated and uninfected control 
cells; p < 0.001. A similar trend was observed for IL-6 and TNF-α gene expression (Figure 8B,C). 
It is worth noting that the effect of MTB on IL-6 was far superior to that of MAP or LPS (MTB: 
19 ± 0.5 vs MAP 10.14 ± 0.5 vs LPS 11.8 ± 0.6. p < 0.05), Figure 8B. However, the increase in 
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IL-6 level following treatment with nicotine of infected macrophages was similar among MAP, 
MTB, and LPS. There was a significant decrease in the expression of the anti-inflammatory CD206 
marker following nicotine treatment of infected macrophages (p < 0.05), Figure 8D. IL-10 showed 
a clear decrease in expression following nicotine treatment of infected macrophages, but it was not 
statistically significant (Figure 8E). 
   To validate that the effect of nicotine on infected cells is mediated through α7nAChRs, we 
blocked nAchR in macrophages with MEC. Treatment with MEC seems to cancel the nicotine 
effect with iNOS expression levels more aligned with those found with MAP infection only (MAP 
+ MEC + N: 67.9 ± 1.42 vs MAP: 71.22 ± 1.54. p < 0.05, Figure 9A). Pro-inflammatory cytokines 
IL-6 and TNF-α also reflected the iNOS results, with MAP infection enhancing their expression, 
nicotine to further increase their expression, and MEC to cancel the nicotine effect back to a MAP 
inflammatory status (Figure 9B,C for IL-6 and TNF-α, respectively). Anti-inflammatory marker 
CD206 and IL-10 cytokine also demonstrated a significant increase in gene expression upon 
nicotine treatment of uninfected macrophages (nicotine: 191.16 ± 2.4 vs control: 116.81 ± 2.6. p 
< 0.05) for CD206. Interestingly, MEC pre-conditioning prevented nicotine-induced CD206 and 
IL-10 gene expression; (114.5 ± 2.2 vs 191.16 ± 2.4. p < 0.05) for CD206 and (79.8 ± 2.1 vs 148.53 
± 3.2. p < 0.05) for IL-10 (Figure 9D,E, respectively). 
Pre-Conditioning Macrophages with Nicotine Protects against Infection-Induced Inflammation 
Prior to Infection 
   Due to the bivalent effect of nicotine in IBD, we wondered whether the timing of infection in 
IBD smokers could determine the direction of the inflammatory shift. To address that, we 
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evaluated the inflammatory profile of macrophages pre-conditioned with nicotine before infection 
with MAP (nicotine exposure prior infection) versus macrophages that were infected with MAP. 
MTB and LPS were used as controls. As shown in Figure 10A, the iNOS level was significantly 
lower in cells preconditioned with nicotine prior to infection (MAP: 22.9 ± 2.8 vs nicotine + MAP: 
17.17 ± 1.5. p < 0.05), (MTB: 29.8 ± 0.8 vs nicotine + MTB: 11.35 ± 1.7. p < 0.05), or (LPS: 35.16 
± 2.04 vs nicotine + LPS: 18.06 ± 1.4); p < 0.05). Similarly, IL-6 and TNF-α gene expression 
results (Figure 10B,C, respectively) corroborated those of iNOS with the lowest values consistently 
reported for cells preconditioned with nicotine prior to infection. M2 cell surface marker CD206 
and IL-10 cytokine, on the other end, showed their highest expression levels (p < 0.05) in cells 
pre-exposed to nicotine prior to infection (Figure 10D,E, respectively). 
Nicotine Increases MAP Burden in Macrophages and Decreases Cellular Apoptosis 
   To determine MAP viability and cellular apoptosis in macrophages treated with nicotine prior 
and post infection, activated THP-1 cells were infected with MAP for 24 h, then treated with 
nicotine (4 µg/mL), and vice versa. As listed in Table 3, nicotine-maintained viability and 
increased the burden of MAP and MTB regardless of the timing of exposure to nicotine prior or 
post infection. For MAP: nicotine + MAP 91.4 ± 5.5, MAP alone 69.4 ± 5.2, and MAP + nicotine 
80.79 ± 4.8. For MTB: nicotine + MTB 92.5 ± 4.6, MTB alone 74.2 ± 3.1, and MTB + nicotine 
85.2 ± 6.2. K. pneumoniae was used as a negative control and the viability was the minimum as 
expected. 
   For apoptosis, active caspase-3 activity increased in MAP infected macrophages when compared 
to control, which was similar to macrophages infected with MTB or treated with LPS (Figure 11). 
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The data also show that the activity of caspase-3 in macrophages was lower in nicotine treated 
macrophages after MAP infection (MAP: 4.81 ± 0.28 vs MAP + nicotine: 3.22 ± 0.05. p < 0.05). 
A similar trend was also observed for MTB and LPS.  
Discussion 
   More studies are needed to elucidate the role of innate immune response in the overall 
inflammatory process in IBD smokers. Limited studies have investigated the effect of CS or 
nicotine on macrophage recruitment, proliferation, and consequent immune response among 
smokers with CD or UC. Extensive studies reported a strong association between microbial 
infection and CD pathogenesis; the opposite is true for UC [29]. Infection of macrophages with 
intracellular microorganisms, such as MAP or AIEC, CD-associated pathogens, leads to pro-
inflammatory response and increase in M1/M2 ratio [30]. On the contrary, nicotine binds to 
α7nAChR on monocytes and the macrophages cell surface and inhibits pro-inflammatory cytokine 
release leading to a decrease in M1/M2 ratio [31,32]. Extensive studies have investigated the effect 
of CS in patients with tuberculosis. Most reports have demonstrated a strong link between smoking 
and increased susceptibility to tuberculosis (TB) infection [33]. For example, studies reported that 
TB smokers have higher levels of alveolar macrophages compared to non-smoker and former 
smokers with TB, which may explain the abnormal innate immune response in these patients 
[33,34]. Since there is strong homology between MAP and MTB, and due to the fact that MAP is 
associated with CD but not UC, we stipulated that the effect of CS on CD smokers might be similar 
to that of tuberculosis. The nicotine-rich HLE extracts induced macrophages to an anti-
inflammatory response due to significant upregulation in IL-10. The opposite effect was observed 
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when macrophages where treated with the nicotine-less LAMD extracts. The finding supports 
earlier observations which suggested that nicotine is a potent agent in tobacco [34,35]. The data 
clearly confirm that the anti-inflammatory effect observed in CS is due to nicotine. We were 
astonished as to how macrophages infected with MAP, or MTB, or even treated with LPS 
responded to exposure to nicotine. We anticipated nicotine to reduce the inflammatory response 
caused by the bacterial infection or the LPS derived from AIEC. Instead, the inflammatory 
response increased as indicated by the upregulation of iNOS, IL-6, and TNF-α. On the other hand, 
CD206 and IL-10 were downregulated (Figure 8D,E). The effect of nicotine, the most active and 
potent ingredient in CS, on infected macrophages is clearly opposite to that seen in uninfected 
macrophages. In absence of infection, nicotine acted as an immunosuppressive drug, increasing 
M2 macrophages and IL-10 cytokine (Figure 10); however, upon MAP infection, the anti-
inflammatory role of nicotine was lost to a robust pro-inflammatory response even higher than that 
observed with infection only (Figure 8). This data is reflective of what is observed in IBD patients.  
   Knowing that some CD patients might be suffering from infection with MAP, AIEC, or possibly 
other microorganisms, which is not the case in UC patients, we propose that the successive 
inflammatory response among some CD smokers is due to bacterial infection associated with the 
disease. Dysbiosis and microbiota shifts have been reported in CD patients, which lead to an 
alteration in the proportion of bacteroides, firmicutes, and enterobacteriaceae [14]. In this study, 
we included MTB as a positive control in order to confirm the expected effect of nicotine on 
macrophages in TB patients. We also included LPS in order to investigate the effect of gram-
negative bacteria, including AIEC and K. pneumoniae that also have been associated with CD 
43 
 
pathogens. The data clearly confirm that the successive inflammatory response observed in CD 
smokers is related to the association of the disease with bacterial infection. 
   Unlike the common knowledge, also confirmed in our study, about the anti-inflammatory effect 
of nicotine, the true effect of nicotine on macrophages depends greatly on the presence or absence 
of infection. A lack of infection in patients with UC should explain why they benefit from CS 
exposure as reported extensively in the literature [35]. In fact, nicotine is currently offered as a 
therapeutic agent for UC; present in many forms, such as nicotine patches, chewing gum, as well 
as nicotine-based enemas, because of its anti-inflammatory proprieties [36,37]. The opposite is 
true in CD smokers who often suffer from bacterial infection.  
Further evidence to support the outcome of this study is the use of MTB as a control. The effect 
of nicotine or HLE extracts on MTB infection was strongly similar to that of MAP infection. Data 
in our study strongly support published reports indicating TB smokers to suffer greatly from 
increased symptoms compared to TB non-smokers [38]. We cannot exclude that the presence of 
oxidative and highly reactive compounds other than nicotine in CS may contribute to the 
successive pro-inflammatory response observed in infected macrophages [39].  
   To confirm and validate our conclusion, we proceeded to determine the mechanism by which 
nicotine modulates macrophages. First, nicotine in this study increased the viability of MAP in 
THP-1 cells (Table 3). This confirms earlier reports from MTB studies which demonstrated that 
nicotine impairs anti-MTB defense within macrophages through α7nAchR, by decreasing 
apoptosis via activation of the NF-ҝB family—this ultimately leading to an increased MTB burden, 
thereof, worsening TB symptoms [33,38]. Among the virulence factors in Mycobacteria that are 
involved in their survival and persistence include Protein Kinase G (PknG) (an enzyme which 
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inhibits phagosome–lysosome fusion) and Protein Tyrosine Phosphatase-A (PTP-A, an enzyme 
that inhibits phagosomal maturation) [40]. Based on the close relatedness between MTB and the 
fact that MAP data in this study are similar to MTB, we propose that MAP survival in macrophages 
follows a mechanism similar seen in MTB. On the other hand, the viability of K. pneumoniae in 
macrophages was poor and most likely due to the lack of these key virulence factors. Clearly, the 
impact of increase in MAP and MTB viability in infected macrophages has caused these immune 
cells to release pro-inflammatory cytokines, including IL-6 and TNF-α, as demonstrated 
continuously and exponentially in this study (Figure 8). Interestingly, we were able to link the 
upregulation in these cytokines to the polarization of macrophages into M1 as demonstrated by 
upregulation of iNOS marker. Second, we observed a significant decrease in macrophages 
apoptosis upon nicotine treatment, which further supports the idea that nicotine increases 
mycobacterial viability by reducing the host’s cell death (Figure 11). Third, nicotine exerts its 
immunosuppressive effect via α7nAChRs on macrophages and other immune cells. These 
receptors are responsible for the activation of cholinergic anti-inflammatory pathway leading to 
decreased secretion of pro-inflammatory cytokines, such as IL-6 and TNF-α in vitro and in vivo 
which confirms earlier reports [41]. Our study confirmed the immunosuppressive effect of pure 
nicotine in THP-1 cells by shifting the polarization to alternative M2 macrophages and increased 
the production of anti-inflammatory cytokine IL-10. Our study further established that abrogation 
of nicotine immune modulatory effect depends on the blockage of its receptor with MEC, a 
pharmacological inhibitor to nAchRs (Figure 3). This data supports an earlier report regarding the 
downregulation of α7nAChRs expression in inflamed CD tissues [32]. 
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   Moreover, we investigated whether pre-conditioning macrophages with nicotine would confer 
protection against infection. Our results indicate that pretreatment of infected macrophages with 
nicotine significantly inhibits the production of pro-inflammatory cytokines (Figure 10B,C). 
Similar findings were reported by a previous study showing that nicotine pretreatment significantly 
decreased IL-6, TNF-α, and IL-12 in Legionella infected macrophages [42]. In addition, pre-
exposing cells to nicotine induces M2 polarization, which may not be canceled or reversed back 
to M1 status following infection (Figure 10). We plan to investigate the ability of M2 to reverse to 
M1 and vice versa. 
   One limitation of this study is that it is an in vitro culture system in which THP-1 cells, an 
immortalized monocyte-like cell line, was used to mimic CD-like macrophages and perhaps 
peritoneal macrophages. We plan to further validate our findings in cells from CD and UC patients 
including peritoneal macrophages and peripheral mononuclear cells. Additionally, using an in vitro 
model system as in this study may suppress the true effect occurring in vivo. Future studies should 
involve investigations of the effect of nicotine and CS and possibly vaping in animals infected 
with CD-associated pathogens.  
   In summary, using an in vitro cell culture system, we were able to mimic a macrophages setup 
similar to those in CD and UC patients with history of prior or active cigarette smoking and in 
correlation with active bacterial infection. The effect of CS on the cellular processes in 
macrophages similar to those in UC active smokers, CD active smokers, and CD non-smokers are 
illustrated in Figure 8. Nicotine in UC active smokers activates the cholinergic anti-inflammatory 
pathway through α7nAChRs leading to M2-macrophage polarization, upregulation of CD206 and 
IL-10, downregulation of iNOS, IL-6, and TNF-α, and significantly decreases caspase-3 activity 
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(Figure 8A). Similar cellular changes are expected in CD active smokers who are not associated 
with infection (Figure 12A). On the contrary, nicotine in CD active smokers associated with 
bacterial infection induce M1-macrophage polarization, upregulation of iNOS, IL-6, and TNF-α, 
downregulation in CD206, IL-10, decrease in caspase-3 activity, and increase in infection burden 
(Figure 12C). CD non-smokers with bacterial infection suffer also from pro-inflammatory 
response but at a lower level (Figure 12B) compared to CD smokers with bacterial infection 
(Figure 8C). Cellular apoptosis is always reduced in macrophages exposed to nicotine. 
   Overall, this is the first study to provide significant insight toward understanding the cellular 
events involved in the mysterious contradictory effect of CS among IBD patients with different 
history of smoking. We plan to investigate the effect of CS ingredients on the molecular processes 
involved in bacterial infection and interaction with nicotine receptors in macrophages mimicking 





Figure 5:Effect of cigarette smoke (CS) and pure nicotine on Mycobacterium avium subsp. 






















Figure 9:Interplay between nicotine, α7nAChR, and mecamylamine (MEC, an nAchR 





Figure 10:Effect of nicotine preconditioning on infected macrophages. 
 
 















Table 3:Effect of nicotine on bacterial viability in macrophages. 
Treatment Group Viability 
Mean ± SD 
(%) 
Fold Change in Viability Prior/Post 
Nicotine Treatment 
K. pneumoniae ATCC 
13883 
3.7 ± 4.5  
MAP UCF4 69.4 ± 5.2  
N(4 µg/mL) + MAP UCF4 91.4 ± 5.5 1.31 
MAP UCF4 + N(4 µg/mL) 80.79 ± 4.8 1.17 
MTB HR237 74.2 ± 3.1  
N(4 µg/mL) + MTB HR237 92.5 ± 4.6 1.25 
MTB HR237 + N(4 µg/mL) 85.2 ± 6.2 1.15 
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CHAPTER THREE: NICOTINE MODULATES MYD88-DEPENDENT SIGNALING 
PATHWAY IN MACROPHAGES DURING MYCOBACTERIAL INFECTION 
Introduction 
   Crohn’s Disease (CD) is one of the relapsing chronic diseases that affects the gastrointestinal 
tract. Although the etiology of CD is still vigorously debated, mounting evidence at the basic and 
clinical research levels has highlighted and strongly associated CD with microbial infection, 
immune-dysregulation, and mucosal dysfunction. Among the most debated pathogens that have 
been studied for their possible role in CD pathogenesis are Mycobacterium avium subspecies 
paratuberculosis (MAP), adherent-invasive Escherichia coli (AIEC), and Klebsiella pneumoniae 
[1-4]. The immune response in patients with CD is unique with clear involvement of both Th1/Th2 
signaling leading to humoral and innate immune response.  Innate immunity is considered an early 
warning system against any pathogenic attachment where macrophages play a crucial role in 
recognizing bacteria through their own cellular receptors such as pattern-recognition receptors 
(PRRs). PRRs are highly expressed in macrophages and are involved in recognition of both 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs) [5]. Furthermore, toll-like receptors (TLRs) are members of the PRR family that have 
been identified as a central hub of pathogen recognition which results in the immune response [6]. 
TLRs are found in most mammals and each of them has specific transmembrane proteins  with 
their own recognition patterns [7].While most TLRs are located on cell surface which play 
important role in recognition of microbial derivatives, TLR3, TLR7, and TLR9 are localized in 
the endosomes and bind mainly to microbial nucleic acids [8]. TLRs recognize their ligands as 
heterodimers in TLR1/TLR2 and TLR6/TLR2, homodimers in TLR3, TLR4, TLR5 and TLR9, 
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and monomers in TLR7 and TLR8  (Table 4). Table 4 summarizes key TLRs and their location 
and functions. 
   Recently, TLRs have been causally linked to play a role in the pathogenesis of inflammatory 
bowel disease (IBD).  Specifically, macrophages in CD patients seem to have high expression of 
TLRs compared to those in patients with Ulcerative Colitis (UC).  We believe the difference in 
macrophage TLRs expression level among IBD subsets  is most likely due to the association of 
CD with intracellular infection. MAP is the causative agent of CD-like disease in animals and has 
been widely reported to be involved in more than 50% of CD cases [2, 10].  It is still unclear which 
TLRs are involved in Mycobacterial infection.  However, mycobacterial cell wall components 
such as lipoarabinomannan (LAM), similar to LPS in gram-negative bacteria, have  been suggested 
to interact with TLRs during infection [11].TLR9 has been reported to recognize and interact with 
mycobacterial DNA in phagosomes following phagocytosis [11-13]. On the other hand, TLR4 is 
confirmed to play a role in recognition of gram-negative bacteria through interaction with LPS 
[12].  
   TLR activation affects downstream signaling pathways including major adaptor proteins such as 
myeloid differentiation primary response 88 (MyD88) [14]. All TLRs, except TLR3, require 
MyD88 to mediate signal transduction pathways in response to inflammatory triggers in 
macrophages [14]. MyD88-dependent signaling pathway was reported to be similar to IL-1 
receptor pathways in activation of IRAK-1, leading to activation of the MAP-kinase and NF-κB 
pathways [14-16]. We speculated that there is a link between the high expression of TLRs in 
macrophages with MyD88-dependent pathway and the pro-inflammatory response during 
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infection in Crohn’s disease. If confirmed, the outcome should support a microbial etiology in CD 
pathogenesis. 
   Autophagy is an effector mechanism used by immune cells to eliminate intracellular bacteria 
[17]..And it has been reported to occur during Mycobacterium tuberculosis infection.  Recent 
studies reported an interplay between vitamin D-dependent antimicrobial response, TLR2, and the 
autophagy pathway leading to enhanced macrophages response against M. tuberculosis infection 
[17-20]. Specifically, they reported that 1,25D3 induces the production of cathelicidin and 
activation of  the autophagy pathway in MTB-infected macrophages resulting in protective 
immune response against M. tuberculosis infection [11]. Given the 90% homology between MTB 
and MAP, we proposed that TLR2-signaling pathway play a critical role in the macrophage 
response during MAP infection in CD.  
   As we reported recently, cigarette smoke (CS) and nicotine exacerbate inflammation in CD 
smokers and provide a protective anti-inflammatory response in UC smokers [21]. Specifically, 
we demonstrated that successive inflammatory response in CD smokers is due to the presence of 
MAP infection in these patients [21,22]. We also elucidated the role of α7nAChR in mediating 
nicotine effect in MAP-infected macrophages  [21]. We reported that nicotine exacerbates MAP 
infection in macrophages by upregulation of iNOS, increasing M1/M2 ratio and pro-inflammatory 
cytokines such as tumor necrosis factor alpha (TNF-α) and IL-6  [21]. Despite the new findings by 
this group, there is a big gap in the literature about how nicotine modulates macrophage recognition 
patterns including TLRs and MYD88 signaling during mycobacterial infection. Specifically, it 
remains not understood how nicotine affects MAP recognition and infection in macrophages 
causing further inflammation and worsening symptoms in CD smokers. This study is focused on 
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the elucidation of the mechanistic role of nicotine in modulating TLR and MyD88-dependent 
signaling pathway in MAP-infected macrophages.  We investigated the interplay between nicotine, 
and TLR2 and TLR4  for their reported role in infection by gram-negative and -positive bacterial 
infection, and subsequent effect on MYD88 signaling, inflammatory response, and bacterial load  
in infected macrophages. 
Materials and methods 
Culture Conditions of THP-1 Macrophages 
…THP-1 monocytes (ATCC TIB-202) were cultured as described earlier [23]. Briefly, cells were 
maintained in RPMI-1640 (ATCC 30-2001) growth medium with 10% fetal bovine serum (FBS; 
Sigma Life Science, St. Louis, MO). The cells then were maintained in a humidified 5% CO2 
incubator at 37oC until they reached 80% confluency. Then, cells were activated by adding 50 
ng/mL of phorbol 12-myristate 13-acetate (PMA; Sigma Life Science, St. Louis, MO) for 24 hours. 
All experiments were performed in duplicates and done within eight passages.  
Infection and Treatment of THP-1 Macrophages 
   Infection: activated THP-1 cells (M0 macrophages) were plated at a density of 3x105 cells in 12 
well plates. Cells were infected for 24 hours at 37o C in 5% CO2  with 1x10
7 CFU/mL of MAP 
strain UCF4 (a clinical strain isolated from CD patient), M. tuberculosis ATCC HR237, or K. 
pneumoniae ATCC13883. Bacterial Lipopolysaccharide (LPS) from E. coli strain O111.B4 
(Sigma Life Science, St. Louis, MO, 5µg/mL), and uninfected cells were used as a control.  
66 
 
   Treatment with nicotine: activated THP-1 macrophages were treated with nicotine (Sigma Life 
Science, St. Louis, MO, 4µg/mL). Cells were incubated for an additional 24 hours at the same 
conditions. 
…Receptor Inhibitors: to determine the role of TLR and MyD88 in the cellular recognition of 
MAP and it interplays with nicotine, activated THP-1 macrophages were pretreated with MMG11 
(TLR2 antagonist; Bio-Techne, MN), TLR4-IN-C34 (TLR4 inhibitor; Sigma-Aldrich, St. Louis, 
MO)  and T6167923 (MYD88 inhibitor; Aobious, MA) (Table 5) separately at room temperature 
for 30 minutes before MAP infection. All experiments were performed in duplicates. 
Measurement of Relative Gene Expression Using RT-PCR 
   RNA Isolation: After 24 hours treatment, cell pellets were collected in 2mL-microcentrifuge and 
then suspended in 500µL of TRIzol ® reagent (Invitrogen, Carlsbad, CA). A 125µL of chloroform 
was added to each tube, mixed and incubated at room temperature 5 minutes.  Following 
centrifugation at 10,000 rpm for 5 minutes, the aqueous phase was transferred to a new tube and 
mixed with 275µL isopropanol. Following centrifugation at 14,000 rpm and 4°C for 15 minutes, 
RNA pellets were isolated, washed in 500µL of 75% ethanol, air-dried, and then dissolved in 15µL 
of Tris-EDTA (TE) buffer. RNA was stored at -80oC until further use. 
   cDNA Synthesis: reverse transcription reaction was carried out by adding 800ng of RNA in 0.25-
mL microtubes containing 20µL of PCR reaction; 4µL iScript™ Reverse transcription (Bio-Rad®) 
and up to 0.20mL RNAse-free water. The reaction was performed using MyGene Series Peltier 
Thermal Cycler under the following conditions: 5 min at 25°C, 20 min at 46°C and 1 min at 95°C.  
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   RT-PCR: gene expression analysis was performed as described earlier [22]. Briefly, a total 
volume of 20µL reaction mixture containing1µL of cDNA (30ng/µL), 10µL of Fast SYBR Green 
Mastermix (Thermo Fisher Scientific, Waltham, MA), 1µL of forward  primer , 1µL of reverse 
primer of either TLR2,TLR4,MyD88, IL-8, iNOS, MMR,TNF-α or IL-10 (Thermo Fisher Scientific, 
Waltham, MA) (Table 6), and 7µL of RNAse-free water, were prepared in a 96-well Microamp 
RT-PCR reaction plate and placed analyzed using 7500 Fast Real- Time PCR System (Applied 
Biosystems, Foster City, CA). Housekeeping GAPDH primer was used to obtain baseline CT 
readings. Relative mRNA expression as fold change was calculated by using the equation 2(−∆∆CT), 
where ∆CT= [(Sample RT-PCR CT value) − (GAPDH CT baseline value)] whereas ∆∆CT=[ 
∆CTTreated - ∆CTUntreated ].  
Measurement of Cell Receptors 
   For cell receptors, cell pellets were incubated with iced RIPA buffer (Thermo-Fisher, Waltham, 
MA) for 15 minutes, then centrifuged at 14000 rpm for 20 minutes at 4°C . Supernatant containing 
cell lysates were analyzed using ELISA kits: TLR2 (RayBiotech, Norcross, GA) and TLR4 
(RayBiotech, Norcross, GA) following manufacturer’s instructions. All ELISA experiments were 
done in duplicates. 
MAP Viability Assay 
   To determine if TLR2 and MYD88 have a role in MAP viability in macrophages, THP-1 
macrophages were blocked by either MMG (5µg/mL) or T6167923 (5µg/mL) followed by MAP 
infection. After 24 hours of infection, THP-1  macrophages were washed twice with PBS to 
remove extracellular bacteria, then THP-1 macrophages were collected at 3 time points: 0, 24, and 
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84 hours. The cells were lysed using iced RIPA buffer (Thermo-Fisher, Waltham, MA), and then 
the samples were centrifuged at 14,000 rpm for 20 min at 4°C. Supernatants were collected and 
the LIVE/DEAD™ BacLight™ Bacterial Viability Kit (ThermoFisher Scientific, Waltham, MA) 
was used according to the manufacturer’s protocol as described earlier [24]. Briefly, 100 µL of 
each sample was loaded into separate wells of a 96-well flat-bottom microplate in triplicate and 
mixed with 100 µL of fluorescent stain solution. The plate was then incubated for 15 min at room 
temperature (RT) in the dark. Fluorescence was measured using a microplate reader at 530 nm to 
determine the proportion of live bacteria (green), and at 630 nm to determine the proportion of 
dead bacteria (red). Data was analyzed by generating a standard plot using fluorescence 
measurements of five different proportions of live to dead MAP including 0:100, 10:90, 50:50, 
90:10, and 100:0. A graph was generated, and the equation of the least-squares fit of the 
relationship between percent live bacteria (x) and green/red fluorescence ratio (y) was used to 
calculate bacterial viability of the MAP-infected macrophages. The experiments were done in 
triplicates. 
Statistical Analysis 
   Statistical analysis was performed by using GraphPad Prism 7.02 software. Significance among 
experiments was assessed by Unpaired Two-tailed t test at p <0.05 and a 95% confidence interval 
(CI). All data collected in this study were pre-tested for normal distribution using the Kolmogorov–





TLR2/TLR4 Expression During Infection in Macrophages 
   In order to determine the effect of bacterial infection on TLR2/TLR4 expressions on 
macrophages, we infected  PMA-activated THP-1 with MAP for 24 hours. MTB and LPS were 
also used as controls. Infection of macrophages with Mycobacteria increased TLR2 in gene and 
protein levels, respectively (MAP: 10.03 ± 0.64, MTB: 10.11 ± 1.02 vs uninfected: 1.20 ± 0.67; p 
< 0.05 for gene; Figure 13A), (MAP: 10.42 ± 0.20, MTB: 11.71 ± 0.42 vs uninfected: 6.15 ± 1.06; 
p < 0.05 for protein; Figure 13B). It is worth mentioning that the effect of mycobacterial infection 
on TLR4 expression was not significant when compared with uninfected untreated cells (Figure 
13C). On the other hand, LPS elevated the expression of TLR2/TLR4 on macrophage at the gene 
level. However, the significant effect was observed more in TLR4 when compared with the 
negative control (LPS: 14.54 ± 1.07 vs uninfected cells: 1.02 ± 0.23 ; p < 0.001) (Figure 13A and 
C). Similar trend was also observed at the  protein level (Figure 13B and D). 
Nicotine Modulates TLR2/TLR4 Expression in Macrophages during infection  
   To determine if nicotine modulates the expression of TLR2/TLR4 in infected macrophages, we 
treated infected macrophages with 4µg/mL of pure nicotine for 24 hours followed by RT-PCR and 
ELISA evaluation of the expression and protein levels TLR2/TLR4. As shown in Figure 13A, 
adding nicotine treatment to infected macrophages significantly decreased TLR2 expression across 
all infections (MAP + nicotine: 2.0 ± 1.04 vs MAP alone: 10.03 ± 0.64; p < 0.05), (MTB+ nicotine: 
2.24 ± 1.14  vs  MTB alone: 10.11 ± 1.02; p < 0.05), or (LPS + nicotine: 3.07 ± 1.40 vs LPS alone: 
8.19 ± 1.01; p < 0.05). The findings were consistent with results from  protein level analysis  
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(Figure 13B) (MAP + nicotine: 1.59 ± 1.13 vs MAP alone: 10.42 ± 0.20; p < 0.05), (MTB+ 
nicotine: 1.44 ± 1.10  vs  MTB alone: 11.71 ± 0.42; p < 0.05), or (LPS + nicotine: 1.52 ± 1.10 vs 
LPS alone: 20.45  ± 2.4; p < 0.05). Similarly, TLR4 expression and protein levels corroborated 
those of TLR2 with lowest values reported after nicotine treatment of infected cells (Figure 13C 
and D). 
Nicotine/TLR2 Interaction Modulates MyD88 Signaling in Macrophages During Infection 
   To determine if MyD88 is the main adaptor protein in TLR2 signaling and to examine the effect 
of nicotine on MyD88 signaling and subsequent pro-inflammatory cytokine IL-8 in macrophage 
during infection, we measured expression of  MyD88 and IL-8 following nicotine treatment of 
MAP-infected macrophages. MTB and LPS were also used as controls. Compared with MAP 
infection alone, nicotine upregulated MyD88 and IL-8 expression, the latter showed more 
noticeable change by 2.5 folds (Figure 14A and B) (MAP + nicotine: 22.3 ± 2.09 vs MAP alone: 
13.39  ± 1.80; p < 0.05, for MyD88 ), (MAP+ nicotine: 6.40 ± 0.52  vs  MAP alone: 3.52 ± 0.62; 
p < 0.05, for IL-8). However, the significant elevation in MyD88  expression was observed in all 
mycobacterial infection with/out nicotine treatment compared to untreated uninfected cells, p < 
0.05. Interestingly, there was no clear change in MyD88 and IL-8 expression when macrophages 




Antagonism of TLR4 Abrogates Macrophages Response Against Gram Negative Bacterial 
Infection  
   To validate the role of TLR4 in macrophages response against bacterial infection, we blocked 
TLR4 with TLR4-IN-C34, an TLR4 antagonist. Specifically, PMA-activated THP-1 macrophages 
were pretreated with 0, 2.5, 5 and 10 µg/mL of TLR4-IN-C34, followed by either treated with LPS 
or infected with MAP. In absence of TLR4-IN-C34, LPS significantly increased iNOS level (3.66 
± 0.66 compared to 1.005 ± 0.125 in macrophages not treated with LPS; p < 0.05). Pretreated 
macrophages with (2.5 to 10 µg/mL) gradually neutralized the effect of LPS on iNOS level and 
reached its optimum effect at 5 µg/mL (Figure 15A). A similar trend was also observed on TNF-
α and IL-8 expressions (Figure 15C and D). Likewise, preconditioning cells with TLR4-IN-C34 
(5 µg/mL) has increased M2-macrophages expression (MMR) (TLR4-IN-C34 (5 µg/mL) + LPS: 
1.10 ± 0.14 vs LPS alone: 0.62  ± 0.06 vs TLR4-IN-C34 (5 µg/mL) alone: 1.12 ± 0.18 ; p < 0.05) 
(Figure 15B). Surprisingly, there was a modest decrease in iNOS, TNF-α and IL-8 levels even with 
high concentration of TLR4-IN-C34 (10 µg/mL) with MAP infection (TLR4-IN-C34 (10 µg/mL) 
+ MAP: 1.92 ± 0.30 vs MAP alone: 2.5  ± 0.25; p < 0.05, for iNOS) (TLR4-IN-C34 (10 µg/mL) + 
MAP: 4.98 ± 0.45 vs MAP alone: 6.50 ± 1.90; p < 0.05, for TNF-α) (TLR4-IN-C34 (10 µg/mL) + 
MAP: 2.67 ± 0.21 vs MAP alone: 3.58  ± 0.51; p < 0.05, for IL-8) (Figure 15A, C and D). 
Antagonism of  MyD88 or TLR2 Alters The Level of Macrophages Response During Infection 
…We showed in the previous experiment that TLR4 has no role during MAP infection; thus, we 
examined the effect of TLR2 and its adaptor protein (MyD88) on macrophages response during 
MAP infection. Activated macrophages were preincubated with 0, 2.5, 5, 10 or 20 µg/mL of  either 
MMG11 (TLR2 antagonist) or T6167923 (MyD88 inhibitor), followed by infected with MAP for 
72 
 
24 hours. Interestingly, MMG11 at 5 µg/mL attenuated the pro-inflammatory status in MAP-
infected macrophages with greatest decrease was observed in TNF-α by almost 4 folds compared 
to MAP infected macrophages alone (MMG11 (5 µg/mL) + MAP: 2.33 ± 0.98 vs MAP alone: 6.50 
± 1.90; p < 0.05) (Figure 16C).  
   On the other hand, 10 µg/mL of T6167923 is the optimum to cancel the macrophages immunity 
against MAP infection by decreasing the expression of TNF-α and IL-8 to levels similar to 
uninfected macrophages (T6167923 (10 µg/mL) + MAP: 1.15± 0.35 vs T6167923 (10µg/mL): 
1.080  ± 0.27; p < 0.05, for TNF-α) (T6167923 (10µg/mL) + MAP: 1.10 ± 0.27 vs T6167923 
(10µg/mL) : 1.25 ± 022; p < 0.05, for IL-8) (Figure 17C and D) and skewing macrophages toward 
alternative M2 phenotype (T6167923 (10 µg/mL) + MAP: 0.92 ± 0.35 vs MAP alone: 0.71  ± 0.10 
vs T6167923 (10 µg/mL) alone: 0.90 ± 0.20 ; p < 0.05, for MMR) (Figure 17B). 
Effect of Nicotine on MyD88 Signaling in Macrophages During Infection 
   To address the effect of nicotine on TLR2/MyD88 signaling in macrophages, we targeted 
macrophages with either 5 µg/mL of MMG11 (TLR2 inhibitor) or 10 µg/mL of T6167923 (MyD88 
inhibitor) in presence and absence of MAP infection and then subjected the cells to nicotine 
treatment.  While the synergy of MAP and nicotine exhibited the highest levels of iNOS (4.62 ± 
0.59) and IL-8 (6.40 ± 0.51) compared to all other groups, blocking  MyD88 or TLR2 subverted 
macrophages response against MAP by reduction iNOS and IL-8 expressions to level similar to 
uninfected macrophages regardless nicotine treatment (Figure 18A and B). The opposite effect 
was observed in anti-inflammatory profile, using TLR2/MyD88 antagonists before MAP infection 
leads to shift polarization toward M2 and increase IL-10 production (Figure 18C and D). It is worth 
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to mention that using MyD88 antagonist before MAP infection significantly boosted the 
immunosuppressive effect of nicotine on macrophages by increasing IL-10 production by 2.5 folds 
comparing with MAP infection alone. 
The Role of Nicotine and TLR-2 /MyD88 Signaling in MAP Survival in Macrophages  
   We previously published that exposure of MAP-infected macrophages to nicotine maintains 
MAP viability and increases its burden in macrophages [21].  Here we studied a possible role for 
TLR2 or MYD88 in MAP survival in macrophages in presence and absence of Nicotine treatment.  
MAP viability in macrophages treated with anti-TLR2 decreased  to 63% but after 48 hours 
infection.  Likewise, MAP viability in macrophages treated with anti-MyD88 decreased  to 55% 
but after 48 hours infection (Figure 719). Nicotine treatment did not alter the viability of MAP 
after TLR2/MyD88 antagonists compared to no nicotine treatment (Figure 719).   
Discussion 
   MAP, a slow growing intracellular bacterium capable of surviving within host macrophages, 
remains one of the most debated etiological agents of CD [10]. Macrophages play an essential role 
during the early immune response against MAP infection. Several pattern recognition receptors 
such as TLRs have been involved in Mycobacterial recognition in macrophages [17]. Among all 
cell surface TLRs, TLR2 and TLR4 have been identified to interact with pathogens through 
specific ligand binding [17]. On the other hand, nicotine, a lipophilic compound, is considered the 
most  active ingredient in tobacco leaves [25]. We have reported recently that nicotine 
immunosuppressive properties in macrophages were lost when macrophages were infected with 
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MAP, M. tuberculosis or treated with LPS. In fact, in our study we showed that nicotine seems to 
exacerbate inflammatory response during infection [21]. These intriguing findings should explain 
the pro-inflammatory role of cigarettes smoking in patients with CD which is contrary to smokers 
with UC.  This rational is based on the extensive literature that associates CD with microbial 
infection. Not much is found in the literature on the mechanism involved in how nicotine 
exacerbation of inflammatory response in infected macrophages. This led us to study a possible 
interaction between nicotine and TLR2/TLR4 in macrophages during infection.  
   It was estimated that each tobacco cigarette contains an average of 8.4 mg of nicotine and the 
average nicotine concentration in a smoker’s venous blood is approximately 2 µg/mL [26]. Of 
course, these estimates are subjective since smokers vary in how much cigarette smokes they use 
daily. Interestingly, 80-90% of nicotine is absorbed by most tissues that have high affinity for 
nicotine which results in several folds greater of nicotine concentration than in venous blood. 
Moreover, the first-pass metabolism of nicotine in the liver contributes to 10 folds increase in 
nicotine concentration in atrial blood compared to venous blood [26]. In this study, we tested 
nicotine at different concentrations and up to 10 µg/mL. Our data demonstrated that the optimum 
activity was reached at 4 µg/mL in macrophages. The optimum concentration of nicotine was 
determined based on maximum activity in macrophages with least cytotoxic effect. We also 
studied the effect of nicotine at different time intervals ranged from 10 min to 48 hours.  We 
determined that 24 hours of nicotine treatment to provide optimum response in macrophages 
especially when included in experiments that involve additional treatment steps such as infection 
or antagonists.  
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   Recent reports suggested the involvement of TLR2 in MTB infection especially with cell wall 
derivatives  [27, 28]. Other study showed that TLR2-deficient mice failed to develop immune 
response against MTB [29]. However, TLR4-deficient mice were active and responded properly 
during  MTB infection [30]. In gram negative bacterial infection and due to LPS molecule, TLR4 
was reported to play a role in recognition of enteric pathogens [28]. In this study, we investigated 
the interaction of MAP, a CD- associated pathogen, with both TLR2 and TLR4.  We observed a 
significant increase in TLR2 expression and in consequent cytokines including TNF-α and IL-8  
in MAP-infected macrophages, there was no change in TLR4 expression in the same cells (Figure 
13). In macrophages treated with TLR-2 antagonist, we observed a significant decrease in 
expression of IL-8 and TNF-α (Figure  16). We concluded that MAP relies on TLR2 during 
infection at least in our macrophage system. In this study we also blocked TLR4 with TLR4-IN-
C34 antagonist which did not affect inflammatory response in MAP-infected macrophages which 
confirms that MAP interaction with TLR2 is key during infection. Similarly, there was limited 
immune response in LPS-treated macrophages blocked with TLR-4 antagonist which confirms 
that gram negative bacterial rely primarily on TLR4 during infection. This finding is consistent 
with observation by other group who reported that TLR-4 knockout mice are resistant to gram 
negative bacterial infection [31]. Together, we observed that blocking of TLR2 reduced 
macrophages response during MAP infection by decreased IL-8 and TNF-α in transcriptional level 
whereas there is a no role of TLR4 in MAP infection. (Figure 15 and 16). 
   In our efforts to understand the effect of cigarette smokes on CD patients, we investigated 
possible interaction between TLR2 and nicotine in CD-like macrophages. The latter included 
activated macrophages infected with MAP or MTB or treated with  LPS to represent gram negative 
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bacteria. .As expected, we did not observe any change in the expression of either TLR2 or TLR4 
in uninflected cells under nicotine exposure. However, in MAP-infected macrophages, nicotine 
has significantly decreased expression of  both TLR2 and TLR4. Our results are consistent with 
similar observations in MTB-infected macrophages derived monocyte (MDMs) and in lung 
epithelial cells  [28, 32]. The present study is the first to our knowledge to report the negative 
effect of nicotine on the expression of TLR2 and TLR4 in macrophages infected with MAP. The 
finding should provide significant insights toward understanding the effect of cigarette smoke on 
worsening inflammation symptoms in CD patients.  
   To understand how nicotine modulates TLR-2 in CD macrophages, we investigated TLR2 
downstream signaling in infected macrophages under nicotine stress. Specifically, we 
characterized the effect of nicotine on MyD88 in association with TLR2 in presence and absence 
of infection. MyD88 was reported to play an essential role in the development of early innate 
immunity against acute MTB infection [33]. This was based on a defective immune response 
against MTB in MyD88-deficient mice [33]. In present study, MAP upregulated MyD88 
expression and increased its specific correspondence of IL-8 (Figure 14). Surprisingly, nicotine 
has further increased MYD88 and IL-8 expression in MAP-infected macrophages. This suggest 
that other TLRs other than TLR2 or TLR4 may be involved in this response. We speculate that 
TLR9 may be involved in this  response based on earlier report in an MTB infection model [34]. 
Whether TLR9 is involved alone or in interaction with other factors remains unclear. We believe 
that TLR9 might interact with TLR2 because of a report by other investigators who observed a 
shared phenotypic characteristics of MTB infection in TLR2 and TLR9 double-deficient mice and 
of MyD88-deficent mice [35]. This study illustrates the crucial role of MyD88 in upregulation of 
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pro-inflammatory genes during MAP infection. Macrophages treated with MyD88 antagonist 
resulted in decreasing in IL-8 and TNF-α levels to level similar to uninfected cells (Figure 17). We 
also observed a synergistic effect between MyD88 antagonist and nicotine as illustrated by shifting 
macrophages polarization to M2 and increasing IL-10 during MAP infection. In the same manner 
nicotine decreased the iNOS and IL-8 levels to minimum after TLR2 blockade in the same cells 
(Figure 18).  
   Collectively, these findings led us to propose that MAP-Nicotine interaction with TLR-2 during 
MAP infection is MyD88-dependent, the opposite is true for TLR-4. Moreover, when TLR2 or 
MyD88 were blocked with antagonists, there was no significant change in MAP load in 
macrophages even after 48 hours exposure to nicotine treatment (Figure 19). This observation 
suggests a key role for TLR2 and MyD88 in MAP recognition and cytokine production but not in 
MAP uptake and internalization in macrophages. 
   While MAP and LPS represent most pathogens associated with CD pathogenesis, there is no 
doubt that individual microbiome content plays a major factor in CD episodes and faltering. CD 
have been intensively studied in regarding of gut microbiome-immune system interaction and it 
has been reported that CD patients have intestinal microbiome dysbiosis, representing by an 
increase of Enterococcus spp. and Bacteroides spp. with a decrease of Firmicutes (Clostridium 
coccoidos, Eubacterium rectale, and Clostridium leptum) and Actinobacteria (high guanine and 
cytosine content bacteria (Propionibacteriaceae & Bifidobacteria)) [36]. An interesting study 
observed a variation in TLR2 and TLR4 expression on lamina propria cells in CD patients. 
Specifically, it showed an upregulation of TLR2 and TLR4 expression in inflammatory cells from 
lamina propria of active CD patients while during homeostasis, TLR2 and TLR4 are presented in 
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small amount suggesting that those receptors may be responsible of the balance between immunity 
and tolerance [37,38]. 
   Overall, the data is intriguing about the role of TLR2 and MyD88 signaling in MAP infected 
macrophages in association with nicotine exposure ( Figure 20). More studies are needed to expand 
on our findings. Specifically, it is important to validate our findings in primary macrophages from 
CD patients with and without MAP infection. Ultimately, it would be the most informative to 













Figure 14: Effect of nicotine on MyD88 signaling and subsequent IL-8 expression in 






Figure 15: TLR4 antagonist abrogates the macrophage response against LPS but not MAP: 






Figure 16: TLR2 antagonist decreases the macrophage response against MAP infection: 
M1, M2, TNF-α, and IL-8 studies. 
 
 
 Figure 17: MyD88 antagonist cancels the macrophage response against MAP infection: 




Figure 18: Effect of nicotine/MAP infection on Inflammatory response following TLR2 and 
MyD88 inhibition in vitro. 
 
 





Figure 20: Schematic illustration the proposed pathway of MAP recognition and 







Table 4: Toll-Like Receptors (TLRs) and their signaling pathways 
TLR Functional architecture Location & their Ligands 
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CHPTER FOUR: CONCLUSION/FUTURE DIRECTIONS 
   CS plays a contradictory role in IBD subsets; it is a risk factor in CD development and provides 
protection in UC. Our study was the first to provide significant insights toward understanding the 
cellular events involved in the mysterious divergent effects of CS ingredients on IBD patients. 
Specifically, using an in vitro cell culture system, we were able to mimic a macrophages setup 
similar to those in CD and UC patients with history of prior or active cigarette smoking and in 
correlation with active bacterial infection. In order to study how the combination of MAP infection 
and nicotine could modulate macrophages, we used THP-1 differentiated macrophages, which are 
easy to obtain, differentiate and polarize. M1 and M2 THP-1 macrophages have the same 
expression profiles as polarized primary macrophages. Specifically, macrophages were 
differentiated from human monocytic cell line THP-1 in the presence of PMA. Consequently, they 
were polarized into M1 or M2 macrophages that express markers similar to polarized macrophages 
obtained from freshly isolated intestinal macrophages.  
   Nicotine in UC active smokers activates the cholinergic anti-inflammatory pathway through 
α7nAChRs leading to M2-macrophage polarization, upregulation of CD206 and IL-10, 
downregulation of iNOS, IL-6, and TNF-α, and significantly decreases caspase-3 activity. Similar 
cellular changes are expected in CD active smokers who are not associated with infection. On the 
contrary, nicotine in CD active smokers associated with bacterial infection induce M1-macrophage 
polarization, upregulation of iNOS, IL-6, and TNF-α, downregulation in CD206, IL-10, decrease 
in caspase-3 activity, and increase in infection burden. CD non-smokers with bacterial infection 




   Moreover, our study was also the first to investigate the role of TLR2 and MyD88 signaling in 
MAP infected macrophages in association with nicotine exposure. We showed that in MAP-
infected macrophages, nicotine has significantly decreased expression of both TLR2 and TLR4. 
MAP upregulated MyD88 expression and increased its specific correspondence of IL-8. 
Surprisingly, nicotine has further increased MyD88 and IL-8 expression in MAP-infected 
macrophages. Thus, this study illustrates the crucial role of MyD88 in upregulation of pro-
inflammatory genes during MAP infection. Collectively, we suggested that MAP-Nicotine 
interaction with TLR-2 during MAP infection is MyD88-dependent. Moreover, when TLR2 or 
MyD88 were blocked with antagonists, there was no significant change in MAP load in 
macrophages even after 48 hours exposure to nicotine treatment. 
   There is no doubt that more studies are needed to investigate the effect of nicotine and CS on the 
microbiome in patients with UC or CD in presence and association of infection.  This area of 
research is intriguing; more studies have reported a strong role for the microbiome in wellness and 
susceptibility to disease in healthy individuals and patients with underlying conditions. While our 
study focused on the effect of nicotine in macrophages infected with MAP or gram-negative 
bacteria (represented by LPS), more studies should be conducted with other microorganisms 
especially those associated with dysbiosis. We also plan to continue on our work investigating the 
effect of nicotine in the two arms of NF-ĸB pathways in MAP-infected macrophages following 
nicotine exposure. We propose that nicotine through α7nAChR induces NF- ĸB signaling pathway 
(survival pathway). The latter induces the expression of the survival genes such as members of the 
Bcl2 family of apoptosis regulator which ultimately reduces apoptosis and increase infection load. 
This may support the idea that nicotine activates NF-κB pathway to escape apoptosis in tumor 
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cells, which has been identified as one of the essential hallmarks of cancer. Specifically, nicotine 
activates survival pathway causing a phosphorylation to p100, which is bound to RelB. After 
phosphorylation, a portion of p100 is degraded in proteosomes, resulting in transcriptionally active 
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